Roche again recognised as sustainability leader by Dow Jones Sustainability Index

Basel, 12 September 2013

For the fifth consecutive year, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognised by the Dow Jones Sustainability Index (DJSI) as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry, based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as benchmark for investors who integrate sustainability considerations into their portfolios.

“We are proud to be recognised as the most sustainable company in our peer group worldwide. We will continue our efforts to do business in a way that contributes to help patients and society through developing new medicines and diagnostics,” said Severin Schwan, CEO of the Roche Group. "Many of today’s challenges require stakeholders to work together and new ways of doing business, such as in increasing access to healthcare around the world. We recognise we can only be successful if we embark on a strategy, where both industry and society benefit in a sustainable manner.”

This year’s DJSI assessment emphasised a number of Roche’s efforts, such as how the company manages innovation, especially the development of new medical products that create value, management of the supply chain and engagement with stakeholders. Roche’s programmes on managing talent and developing future leaders received the highest points, as did customer relationship management. Roche also scored highly in the areas of marketing practices, human rights, environmental reporting and its contribution to improve health outcomes.

In 2009 Roche introduced a number of five-year corporate goals, using Key Performance Indicators to measure progress. Among these, Roche introduced a diversity objective to increase the percentage of women in key positions by at least 50 percent, as well as an energy-efficiency goal of reducing energy consumption and increasing energy efficiency by 10 percent by the end of 2014. Roche is well on track with these and other goals.

About the Dow Jones Sustainability Indices (DJSI)

The Dow Jones Sustainability™ Indices are maintained collaboratively by S&P Dow Jones Indices and RobecoSAM. Following a best-in-class approach, the indices measure the performance of the world’s sustainability leaders. RobecoSAM invites over 3,000 publicly traded companies, including 800 companies in emerging markets, to participate. Companies are selected for the indices based on a comprehensive assessment of long-term economic, environmental and social criteria that account for general as well as industry-specific sustainability trends. Only firms that lead their industries based on this assessment are included in the indices. The indices are created and maintained according to a systematic methodology, allowing investors to appropriately benchmark sustainability-driven funds and derivatives over the long term. Based on the Global Industry Classification System (GICS), RobecoSAM annually identifies the top company in each of the 24 industry groups. For additional information on the DJSI please visit the official index web site at

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit